The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.
CSO Desmond Pink discusses Nanostics' productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.
Flying with @AirCanada? Pick up En Route magazine and read "19 Canadian Start-ups That Are Out to Change the World." Written by Danielle Groen and illustrated by Martina Paukova.
Global Edmonton Health reporter Su-Ling Goh highlighted 5 amazing medical technologies and treatments from Edmonton research teams and ClarityDX Prostate was one of them!
Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer.
EDMONTON — Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations...
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
Alberta men diagnosed with prostate cancer could soon have a better blood test to help determine if they can bypass a painful and invasive biopsy.
The PSA test for prostate cancer has been linked to unnecessary treatments and biopsies. That’s prompted researchers to start developing a more accurate prostate cancer detection tool.
NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.
Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.
We are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs (www.APCaRI.ca) robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in the Journal of Clinical Oncology - Clinical Cancer Informatics. Thank you to the Alberta Cancer Foundation and many others for their support.
Author: AUTHOR: MARIA CUTUMISU, CATALINA VASQUEZ, MAXWELL UHLICH, PERRIN H. BEATTY, HOMEIRA HAMAYELI-MEHRABANI, RUME DJEBAH, ALBERT MURTHA, RUSSELL GREINER, AND JOHN D. LEWISThis is a micro-review of an original research article from the Lewis research group that identified multiple novel metastasis-blocking targets, by using a whole genome screen and intravital imaging approach, that could be used as therapeutic targets to inhibit solid tumour cell motility.
Author: Konstantin Stoletov, Lian Willetts, Perrin H. Beatty, and John D. Lewis
Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held in Berlin this November. Some travel expenses will be paid for.
CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award.